Skip to search boxSkip to navigationSkip to main content

Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab

  • Yasmin Abaza
    ,
  • Hagop Kantarjian
    ,
  • Guillermo Garcia-Manero
    ,
  • Elihu Estey
    ,
  • Gautam Borthakur
    ,
  • Elias Jabbour
*Corresponding author for this work
  • University of Texas MD Anderson Cancer Center
    ,
  • University of Washington
    ,
  • University of Medicine and Dentistry of New Jersey
    ,
  • University of California at Irvine
Scholary Output:
Contribution to journal
Article
Research
Peer-review

Open access

Abstract

<p>The combination of all-trans-retinoic acid (ATRA) plus arsenic trioxide (ATO) has been shown to be superior to ATRA plus chemotherapy in the treatment of standard-risk patients with newly diagnosed acute promyelocytic leukemia (APL). A recent study demonstrated the efficacy of this regimen with added gemtuzumab ozogamicin (GO) in high-risk patients. We examined the long-term outcome of patients with newly diagnosed APL treated at our institution on 3 consecutive prospective clinical trials, using the combination of ATRA and ATO, with or without GO. For induction, all patients received ATRA (45 mg/m<sup>2</sup> daily) and ATO (0.15 mg/kg daily) with a dose of GO (9 mg/m<sup>2</sup> on day 1) added to high-risk patients (white blood cell count, >10 × 10<sup>9</sup>/L), as well as low-risk patients who experienced leukocytosis during induction. Once in complete remission, patients received 4 cycles of ATRA plus ATO consolidation. One hundred eighty-seven patients, including 54 with high-risk and 133 with low-risk disease, have been treated. The complete remission rate was 96% (52 of 54 in high-risk and 127 of 133 in low-risk patients). Induction mortality was 4%, with only 7 relapses. Among low-risk patients, 60 patients (45%) required either GO or idarubicin for leukocytosis. Median duration of follow-up was 47.6 months. The 5-year event-free, disease-free, and overall survival rates are 85%, 96%, and 88%, respectively. Late hematological relapses beyond 1 year occurred in 3 patients. Fourteen deaths occurred beyond 1 year; 12 were related to other causes. This study confirms the durability of responses with this regimen.</p>

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Research
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 1275-1283 (9 pages)

Journal (Volume, Issue Number)

Blood (Volume 129, Issue 10)

Publication milestones

  • Published - 03/09/2017

Publication status

Published - 03/09/2017

ISSN

0006-4971

Publication IDs

  • Scopus: 85015251442
  • PubMed: 28003274
  • ORCID: /0000-0002-8636-1071/work/68811276

Publication metrics

Metrics

Fractional count
1
Fractional count
0.04
Fractional count
27
Fractional count
0.96
Fractional count
1
Fractional count
1
SciVal
citations
113
SciVal
FWCI
7.01
SciVal
Author count
28
SciVal
Paper percentile
99
SciVal
Top percentile
1
Scopus
citations

PlumX, opens in new tab

Citation count
265
Captures
202
Social media
3
Mentions
2

Funding Details

FunderFunding number
NCI
P30CA016672